{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:14:38Z","timestamp":1788243278243,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mineralocorticoid receptor antagonists (MRAs) are a central component of contemporary cardiorenal protection in chronic kidney disease (CKD). Classic steroidal MRAs, spironolactone and eplerenone, have long been used to treat hypertension and heart failure and to reduce albuminuria, but their wider use in CKD has been constrained by hyperkalaemia and endocrine side-effects. Nonsteroidal MRAs (nsMRAs), typified by finerenone, were developed to maintain antiproteinuric and antifibrotic efficacy while improving tissue selectivity, pharmacokinetics, and tolerability. Large outcome trials in type 2 diabetes with albuminuric CKD show that finerenone reduces the risk of kidney failure and major cardiovascular events when added to renin\u2013angiotensin system (RAS) blockade and, more recently, in combination with SGLT2 inhibition. At the same time, the superior blood pressure\u2013lowering capacity, low cost, and global availability of steroidal MRAs remain compelling, particularly in resistant hypertension and resource-constrained settings. This pro\/con debate contrasts the case for nsMRAs with that for classic steroidal MRAs and explores how best to deploy each class across heterogeneous CKD populations.<\/jats:p>","DOI":"10.1093\/ckj\/sfag280","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:47:38Z","timestamp":1786798058000},"source":"Crossref","is-referenced-by-count":0,"title":["PRO\/CON debate: nonsteroidal versus steroidal mineralocorticoid receptor antagonists in chronic kidney disease: progress, pragmatism, and remaining uncertainties"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-7100","authenticated-orcid":false,"given":"Rajiv","family":"Agarwal","sequence":"first","affiliation":[{"name":"Indiana University School of Medicine and Richard L. Roudebush VA Medical Center , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liffert","family":"Vogt","sequence":"additional","affiliation":[{"name":"Department Internal Medicine, Section of Nephrology, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]},{"name":"Diabetes and Hypertensive Diseases, Amsterdam Cardiovascular Sciences, Amsterdam UMC , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Floege","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Immunology, RWTH Aachen University Hospital , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Zoccali","sequence":"additional","affiliation":[{"name":"Associazione Ipertensione, Nefrologia, Trapianto Renale (IPNET) , Reggio Cal ,","place":["Italy"]},{"name":"Institute of Biology and Molecular Genetics , Ariano Irpino ,","place":["Italy"]},{"name":"Renal Research Institute , NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"2026090101314706500_bib1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2026090101314706500_bib2","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD)","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026090101314706500_bib3","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes (FIGARO-DKD)","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090101314706500_bib4","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2026090101314706500_bib5","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction (FINEARTS-HF)","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026090101314706500_bib6","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"2026090101314706500_bib7","first-page":"3127","article-title":"Low-dose spironolactone and cardiovascular outcomes in moderate-stage chronic kidney disease (BARACK-D): a randomized controlled trial","volume":"30","author":"Hunter","year":"2024","journal-title":"Nat Med"},{"key":"2026090101314706500_bib8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(25)01194-8","article-title":"Spironolactone in patients on long-term haemodialysis (ALCHEMIST), with prespecified meta-analysis of mineralocorticoid receptor antagonist trials in dialysis","volume":"406","author":"Rossignol","year":"2025","journal-title":"Lancet"},{"key":"2026090101314706500_bib9","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026090101314706500_bib10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Combination of finerenone and empagliflozin in patients with chronic kidney disease and type 2 diabetes (CONFIDENCE): a randomised, double-blind, double-dummy, placebo-controlled trial","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026090101314706500_bib11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/ndt\/gfs429","article-title":"Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases","volume":"28","author":"Morales","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2026090101314706500_bib12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/10641963.2016.1246564","article-title":"Addition of spironolactone in patients with resistant hypertension: a meta-analysis of randomized controlled trials","volume":"39","author":"Liu","year":"2017","journal-title":"Clin Exp Hypertens"},{"key":"2026090101314706500_bib13","doi-asserted-by":"publisher","first-page":"S202","DOI":"10.1097\/01.ASN.0000032489.33856.53","article-title":"Renoprotection: a matter of blood pressure reduction or agent characteristics?","volume":"13","author":"Vogt","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2026090101314706500_bib14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2215\/CJN.01040905","article-title":"Double-blind, placebo-controlled study on the effect of spironolactone in patients with persistent proteinuria receiving long-term ACE-inhibitor therapy with or without an ARB","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026090101314706500_bib15","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"2026090101314706500_bib16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","article-title":"Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial","volume":"54","author":"Edwards","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026090101314706500_bib17","doi-asserted-by":"publisher","first-page":"e26904","DOI":"10.1371\/journal.pone.0026904","article-title":"Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease: a randomized cross-over study","volume":"6","author":"Boesby","year":"2011","journal-title":"PLoS One"},{"key":"2026090101314706500_bib18","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026090101314706500_bib19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2604625","article-title":"Finerenone in persons with chronic kidney disease without diabetes","volume":"395","author":"Heerspink","year":"2026","journal-title":"N Engl J Med"},{"key":"2026090101314706500_bib20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jchf.2022.06.010","article-title":"Steroidal MRA across the spectrum of renal function: a pooled analysis of RCTs","volume":"10","author":"Ferreira","year":"2022","journal-title":"JACC: Heart Fail"},{"key":"2026090101314706500_bib21","doi-asserted-by":"publisher","first-page":"gfag150","DOI":"10.1093\/ndt\/gfag150","article-title":"Systolic blood pressure and albuminuria reduction mediate cardiovascular benefits of finerenone in type 2 diabetes and chronic kidney disease","author":"Agarwal","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"2026090101314706500_bib22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease: mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2026090101314706500_bib23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000515811","article-title":"Improving renoprotective therapy by targeting the body sodium balance","volume":"52","author":"Vogt","year":"2021","journal-title":"Am J Nephrol"},{"key":"2026090101314706500_bib24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"},{"key":"2026090101314706500_bib25","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"key":"2026090101314706500_bib26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"2026090101314706500_bib27","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)02064-1","article-title":"New drug therapies for hypertension","volume":"407","author":"Azizi","year":"2026","journal-title":"Lancet"},{"key":"2026090101314706500_bib28","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.ekir.2023.04.016","article-title":"Managing hyperkalaemia in the modern era: a case-based approach","volume":"8","author":"Massicotte-Azarniouch","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026090101314706500_bib29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.34067\/KID.0006782020","article-title":"Patiromer and spironolactone in resistant hypertension and advanced chronic kidney disease: analysis of the randomised AMBER trial","volume":"2","author":"Agarwal","year":"2021","journal-title":"Kidney360"},{"key":"2026090101314706500_bib30","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/13543784.2021.2002844","article-title":"Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics","volume":"30","author":"Barrera-Chimal","year":"2021","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag280\/70672394\/sfag280.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/9\/sfag280\/70672394\/sfag280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/9\/sfag280\/70672394\/sfag280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:31:53Z","timestamp":1788240713000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag280\/8762891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag280","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,17]]},"article-number":"sfag280"}}